tixagevimab   Click here for help

GtoPdb Ligand ID: 11330

Synonyms: AZD8895 | COV2-2196
Compound class: Antibody
Comment: Tixagevimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2 [2]. It was developed by AstraZeneca. This mAb blocks spike binding to ACE2 and prevents infection in animals. Tixagevimab is designed to be a long-acting agent, and in combination with cilgavimab, is proposed as a therapeutic for those people who are likely to respond poorly to SARS-CoV-2 vaccines, or who cannot be vaccinated for any reason, including those who are immunocompromised [1].
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
11776 tixagevimab
Synonyms Click here for help
AZD8895 | COV2-2196
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1111
Other databases
GtoPdb PubChem SID 434321765
Search PubMed clinical trials tixagevimab
Search PubMed titles tixagevimab
Search PubMed titles/abstracts tixagevimab